Selective arterial embolisation for intractable vaginal haemorrhage in genital tract malignancies

Purpose of investigation: Embolisation of the internal iliac artery has been described as an effective and safe method of treating massive vaginal haemorrhage in small series of advanced uterine cancer and case reports of cervical cancer. Selective embolization of the bleeding vessel is potentially less morbid. The aim of this study was to assess the efficacy of selective arterial embolisation (SAE) in controlling intractable haemorrhage due to gynaecological malignancy. Materials and Methods: This retrospective observational study comes from in a tertiary cancer center with 300 new gynecologic cancers per annum. The authors reviewed all gynecology cancer patients who had intractable major vaginal haemorrhage in the first five years following the introduction of selective arterial embolisation at their unit. The outcomes measured were the control of acute haemorrhage and discharge to planned pathway of treatment. Results: SAE was successful in all cases. Identification of the bleeding point facilitated highly selective embolisation in more than half of the patients. The uterine arteries were embolised in the remaining cases. Bleeding stopped immediately. The expedient control of haemorrhage facilitated early discharge to commencement/continuation of radiation treatment or palliative care as appropriate. Conclusions: Since the introduction of SAE the authors have avoided emergency radiotherapy, surgery, and repeat vaginal packing in patients with intractable vaginal bleeding due to gynaecological cancer. Patients were discharged to their appropriate treatment pathways in a timely manner. The authors recommend the application of SAE.

Selective arterial embolisation; Intractable vaginal haemorrhage; Gynaecological malignancy.

[1] Bree R.L., Goldstein H.M., Wallace S.: “Transcatheter embolization of the internal iliac artery in the management of neoplasms of the pelvis”. Surg. Gynecol. Obstet., 1976, 143, 597.

[2] Grace D.M., Pitt D.F., Gold R.E.: “Vascular embolization and occlusion by angiography techniques as an aid or alternative to operation”. Surg. Gynecol. Obstet., 1976, 146, 469.

[3] Hendrickx P., Orth G., Grunert J.: “Embolisation of bleeding pelvic lesions from benign origin – long-term results”. J. Belge. Radiol., 1995, 78, 339.

[4] Hutchins F.L. Jr., Worthington-Kirsch R.: “Embolotherapy for myoma-induced menorrhagia”. Obstet. Gynecol. Clin. North Am., 2000, 27, 397.

[5] Baakdah H., Tulandi T.: “Uterine fibroid embolization”. Clin. Obstet. Gynaecol., 2005, 48, 361.

[6] Li X., Wang Z., Chen J., Shi H., Zhang X., Pan J., et al.: “Uterine arteryembolization for the management of secondary po stpartumhaemorrhage associated with placenta accrete”. Clin. Radiol., 2012, 67, 71.

[7] Hori A.: “Complications following transcatheter arterial embolization for haemorrhage assoiciated with pelvic fracture”. Nihon Igaku Hoshasen Gakkai Zasshi, 1991, 51, 365.

[8] Godier A., Samana C.M., Susen S.: “Management of massive bleeding in 2013: seven questions and answers”. Transfus. Clin. Biol., 2013, 20, 55.

[9] Sommeijer D.W., Sjoquist K.M., Friedlander M.: “Hormonal treatment in recurrent and metastatic gynaecological cancers: a review of the current literature”. Curr. Oncol. Rep., 2013, 15, 541.

[10] Fletcher G.H.: “Text book of radiotherapy”. Philadelphia, PA: Lea & Febiger, 1980, 730.

[11] Biswal B.M., Lal P., Rath G.K., Mohanti B.K.: “Hemostatic radiotherapy in carcinoma of the uterine cervix”. Int. J. Gynecol. Obstet., 1995, 50, 281.

[12] Kim D.H., Lee J.H., Ki Y.K., Nam J.H., Kim W.T., Jeon H.S., et al.: “Short-course palliative radiotherapy for uterine cervical cancer”. Radiat. Oncol. J., 2013, 31, 216.

[13] Chattopadhyay S.K., Deb Roy B., Edrees Y.B.: “Surgical control of obstetric hemorrhage: hypogastric artery ligation or hysterectomy?” Int. J. Gynecol. Obstet., 1990, 32, 345.

[14] Mihmanli I., Cantasdemir M., Kantarci F., Halit Yilmaz M., Numan F., Mihmanli V.: “Percutaneous embolization in the management of intractable vaginal bleeding”. Arch. Gynecol. Obstet., 2001, 264, 211.

[15] Tinelli A., Prudenzano R., Malvasi A., Santantonio M., Lorusso V.: “Emergency endovascular nanopharmacologic treatment in advanced gynaecological cancers”. Int. J. Gynecol. Cancer, 2010, 20, 1250.

[16] Albu S., Grigoriu C., Vasiliu C., Olaru I., Horhoianu I., Grigoras M., et al.: “The role of uterine artery embolizaton in cervical cancer - single case report”. Maedica (Buchar.), 2011, 6, 137.

[17] Dietz D.M., Stahlfeld K.R., Bansal S.K., Christopherson W.A.: “Buttock necrosis after uterine artery embolization”. Obstet. Gynecol., 2004, 104, 1159.

[18] Yeagley T.J., Goldberg J., Klein T.A., Bonn J.: “Labial necrosis after uterine artery embolization for leiomyomata”. Obstet. Gynecol., 2002, 100, 881.

[19] Sieber P.R.: “Bladder necrosis secondary to pelvic artery embolization: case report and literature review”. J. Urology, 1994, 151, 422.

[20] Payne J.F., Robboy S.J., Haney A.F.: “Embolic microspheres within ovarian arterial vasculature after uterine artery embolization”. Obstet. Gynecol., 2002, 5, 883.

[21] Yalvac S., Kayikcioglu F., Boran N., Tulunay G., Kose M.F., Bilgic S., et al.: “Embolization of uterine artery in terminal stage cervical cancers”. Cancer Invest., 2002, 20, 754.

[22] Verheij M., Dewit L.G., Boomgaard M.N., Brinkman H.J., van Mourik J.A.: “Ionizing radiation enhances platelet adhesion to the extracellular matrix of human endothelial cells by an increase in the release of von Willebrand factor”. Radiat. Res., 1994, 137, 202.

[23] Yarnold J., Brotons M.C.: “Pathogenetic mechanisms in radiation fibrosis”. Radiother. Oncol., 2010, 97, 149.

[24] Hodson D.I., Krepart G.V.: “Once-monthly radiotherapy for the palliation of pelvic gynecological malignancy”. Gynecol. Oncol., 1983, 16, 112.

[25] Song S., Rudra S., Hasselle M.D., Dorn P.L., Mell L.K., Mundt A.J., et al.: ‘The effect of treatment time in locally advanced cervical cancer in the era of concurrent chemoradiotherapy”. Cancer, 2013, 119, 325. [26] Nugent E.K., Case A.S., Hoff J.T., Zighelboim I., DeWitt L.L., Trinkhaus K., et al.: “Chemoradiation in locally advanced cervical carcinoma: an analysis of cisplatin dosing and other clinical prognostic factors”. Gynecol. Oncol., 2010, 116, 438.

[27] Chen S.W., Liang J.A., Yang S.N., Ko H.L., Lin F.J.: “The adverse effect of treatment prolongation in cervical cancer by high-dose-rate intracavitary brachytherap”. Radiother. Oncol., 2003, 67, 69.

[28] Perez C.A., Grigsby P.W., Castro-Vita H., Lockett M.A.: “Carcinomaof the uterine cervix. I. Impact of prolongation of overall treatment time and timing of brachytherapy on outcome of radiation therapy”. Int. J. Radiat. Oncol. Biol. Phys., 1995, 32, 1275.

[29] Gmelin E., Jansen O., Weiss H.D., Baumgartner A., Klink F.: “Percutaneous embolization of bleeding tumors of the uterine cervix withcoils”. Geburtshilfe Frauenheilkd., 1989, 49, 24. [30] Smith D.C., Wyatt J.F.: “Embolization of the hypogastric arteries in the control of massive vaginal bleeding”. Obstet. Gynecol., 1977, 49, 317.